PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-63.84%
Negative EBIT growth while TRVN is at 14.24%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-63.84%
Negative operating income growth while TRVN is at 14.24%. Joel Greenblatt would press for urgent turnaround measures.
-88.24%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-87.91%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-87.91%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-63.84%
Negative OCF growth while TRVN is at 37.31%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-63.84%
Negative FCF growth while TRVN is at 37.31%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
53.61%
10Y OCF/share CAGR in line with TRVN's 49.15%. Walter Schloss would see both as similarly efficient over the decade.
53.61%
Positive OCF/share growth while TRVN is negative. John Neff might see a comparative advantage in operational cash viability.
53.61%
Positive 3Y OCF/share CAGR while TRVN is negative. John Neff might see a big short-term edge in operational efficiency.
35.25%
Net income/share CAGR at 50-75% of TRVN's 60.68%. Martin Whitman might question if the firm’s product or cost base lags behind.
35.25%
Positive 5Y CAGR while TRVN is negative. John Neff might view this as a strong mid-term relative advantage.
35.25%
Positive short-term CAGR while TRVN is negative. John Neff would see a clear advantage in near-term profit trajectory.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1280.26%
Positive asset growth while TRVN is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
-28.60%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
50.95%
We have some new debt while TRVN reduces theirs. John Neff sees the competitor as more cautious unless our expansions pay off strongly.
No Data
No Data available this quarter, please select a different quarter.
47.25%
SG&A growth well above TRVN's 10.57%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.